Sera and colonic tissue-bound immunoglobulin extracts from patients with ulcerative colitis and disease controls were examined immunohistochemically and by killer cell cytotoxicity assay for the presence of anticolonic epithelial autoantibodies. IgG yields in the tissue extracts from patients with colitis and control subjects were similar, and the extracts were uniformly autoantibody negative. Of 41 sera from patients with inflammatory bowel disease, 'classical' anticolon antibody was present in 41% and was commoner in patients with sclerosing cholangitis. Cytotoxic anticolon antibody was present in 20% overall and was strongly associated with disease activity; it did not correlate with the presence of 'classical' anticolon antibody. The heterogeneous and non-universal antiepithelial auto-
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Circulating autoantibodies to colonic epithelial cells have been shown by various techniques in a proportion of patients with ulcerative colitis. The best characterised of these activities are the 'classical' anticolon antibody (Fig 1) , with affinity for colonic mucopolysaccharide,'-3 and antibody capable of mediating colonocyte specific cytotoxicity." The relation between these antibodies remains unclear, and their importance in the pathogenesis of ulcerative colitis is uncertain.
Assessment of autoantibody activity at the site of disease will clearly provide more direct information on which to base an assessment of the pathogenetic importance of autoantibody to colonic epithelium because the peripheral blood does not necessarily reliably reflect the situation in the mucosa. Das and colleagues have described a colon bound colitis associated autoantibody (CCA) which is claimed to be highly specific for ulcerative colitis and extractable from almost all colons showing total active disease.79 The corresponding antigen has been characterised as a 40 kDa epithelial membrane protein which is expressed by colon, gall bladder, and skin,9'0 possibly providing an immunological explanation for some of the biliary and cutaneous manifestations of ulcerative colitis." The phenomenon of CCA, however, has yet to be confirmed by independent investigators. This study was designed to attempt to confirm the existence of CCA, and to assess the prevalence of and relationship between CCA, classical anticolon antibody, and cytotoxic anticolon antibody in patients with ulcerative colitis. 
Results

IMMUNOGLOBULIN YIELD
The IgG yields in the colonic extracts ranged from less than 0-1 ,ug/g to almost 1 mg/g wet weight, with a skewed distribution (Fig 2) . There was no significant difference between the two patient groups.
CYTOTOXICITY ASSAY Preincubation viability of both target and effector cell populations exceeded 95%. Mean spontaneous lysis was 9.7%. The intra-assay coefficient of variation for experimental lysis in a typical batch was 15-4%. Estimated interassay coefficient of variation for experimental lysis was 48-3%. Lysis was above the normal range (control mean (+2 SD) 9.3%) for eight (20%) of the sera from patients with inflammatory bowel disease overall, and this subgroup included patients both with ulcerative colitis and Crohn's disease (Fig 3) . All eight sera exhibiting enhanced specific lysis were from patients with active disease (X2=6-42; p<0.025), giving an overall prevalence of 36% in the active disease subgroup. In the subgroup with active ulcerative colitis, four of eight with extensive disease and none of nine with distal disease had supranormal specific lysis. None of the nine sera from patients with primary sclerosing cholangitis and inactive bowel disease had enhanced specific lysis.
The cytotoxicity assay failed to provide evidence of antibody with affinity for HT29 cells in the tissue immunoglobulin extracts examined, and almost all values fell within the serological normal range. There was no significant difference in specific lysis values for group A and group B (Fig 3) .
IMMUNOHISTOCHEMISTRY
Classical anticolon antibody (Fig 1) was present in 17 (41%) of the sera from patients with inflammatory bowel disease and in none of the sera from control subjects (x2=9-53; p<0005).
There was no significant difference between ulcerative colitis and Crohn's disease or between active and inactive inflammatory bowel disease in the prevalence of detectable antibody. Six of the 10 sera from patients with primary sclerosing cholangitis were antibody positive.
Immunohistochemical studies with the colonic immunoglobulin extracts using two-stage immunoperoxidase and ABC techniques failed to provide any evidence of antibody with affinity for colonic epithelium, intrahepatic biliary epithelium, or liver parenchyma.
CORRELATION BETWEEN ANTIBODY ACTIVITIES
There was no correlation between the presence of classical and cytotoxic anticolon antibody in the sera from patients with inflammatory bowel disease. Overall, 56% ofpatients were positive in one or both assays; the prevalence rose to 73% for those with active disease. The results are summarised in Table III .
Discussion
This study confirms the previously reported characteristics of classical anticolon antibody in inflammatory bowel disease.'-' The lack of association with disease extent and activity, absence from the sera of most patients with the disease, and evident lack of cytotoxic activity all strongly suggest that this antibody is merely an epiphenomenon. The suggestion of an increased prevalence of the classical antibody in patients with primary sclerosing cholangitis is also confirmed3; this largely accounts for the higher overall prevalence of the antibody found in this study than reported elsewhere.
The killer cell assay is a highly sensitive technique for detecting cell bound IgG.'2 The technique, however, is critically dependent on the prevailing conditions, reflected by the high interassay coefficient of variation in this study. HT29 cells were used as targets in preference to extracted colonic epithelial cells because of the potential problems with standardisation and the high spontaneous death rate associated with the latter. HT29 cells are relatively well differentiated and show a number of the characteristics of normal colonic epithelium such as polarity and 'tight junctions','3 but the assumption must be made that they express all relevant antigens expressed by colonic epithelial cells.
In four published studies the capacity of serum from patients with inflammatory bowel disease to mediate antibody dependent cytotoxicity for colonic epithelial cells has been assessed. ' 
